Monoclonal Or Polyclonal Antibody Or Immunoglobulin Or Fragment Thereof That Is Conjugated Or Adsorbed (e.g., Adsorbed To A Solid Support, Etc.) Patents (Class 530/391.1)
  • Patent number: 11946055
    Abstract: Disclosed herein are methods, compositions, and kits for engineering proteins using error-prone orthogonal replication (epOrthoRep) and yeast surface display (YSD).
    Type: Grant
    Filed: December 9, 2021
    Date of Patent: April 2, 2024
    Assignees: The Regents of the University of California, President and Fellows of Harvard College
    Inventors: Chang C. Liu, Alon Wellner, Ziwei Zhong, Arjun Ravikumar, Andrew Kruse, Conor Thomas McMahon
  • Patent number: 11938194
    Abstract: The invention provides modified heavy chain constant regions including a cysteine at position 295 by EU numbering and optionally at position 239 by EU numbering. These cysteine residues provide sites for conjugation to a drug or label. When both cysteines are present in a normal heterodimeric antibody format, there are four such sites per molecule of antibody allowing a stoichiometry of one molecule of antibody to four of drug or label. Selection of the cysteine at position 295 with or without cysteine at position 239 is advantageous over cysteines at many other positions due to ease of expression, stability and cytotoxicity.
    Type: Grant
    Filed: February 28, 2018
    Date of Patent: March 26, 2024
    Assignee: SEAGEN INC.
    Inventors: Andrew Waight, Chris Leiske, Travis Biechele, Django Sussman, Patrick Burke, Jocelyn Leiske
  • Patent number: 11912754
    Abstract: The present application provides an antibody fusion protein comprising a vascular endothelial growth factor receptor (VEGFR) fused to the C-terminus of the antibody light chain. Also provided are methods of making and using these antibody fusion proteins.
    Type: Grant
    Filed: October 11, 2018
    Date of Patent: February 27, 2024
    Assignee: IMMUNOWAKE INC.
    Inventor: Xiaoyun Wu
  • Patent number: 11912755
    Abstract: Materials and methods for using polypeptides containing fragments and variants of endostatin to treat fibrosis are described herein.
    Type: Grant
    Filed: November 9, 2020
    Date of Patent: February 27, 2024
    Assignees: Bio, Inc., Novici Biotech LLC, MUSC Foundation for Research Development
    Inventors: Carol Feghali-Bostwick, Terence E. Ryan, Hal S. Padgett, Matthew McGee
  • Patent number: 11912751
    Abstract: This invention discloses a bifunctional TGF-B/immune checkpoint fusion gene and protein with anti-inflammatory activity that represents a new class of therapy for Immune disorders, immune dysregulation, and autoimmune diseases. The bifunctional TGF-B/immune checkpoint fusion gene and protein include: (i) a TGF-B domain consists of TGF-B1 (ii) an immune checkpoint consisting of PD-L1, (iii) a flexible peptide linker that links two TGF-B domains resulting in a dimeric TGF-B construct wherein the dimeric form of the TGF-B ligand is important for its binding and functional activity, and (iv) a rigid peptide linker, wherein the dimeric TGF-B ligand is linked to the immune checkpoint ligand. A unique feature of this invention is the engineering of a dimeric TGF-B1 domain in the TGF-B1/PD-L1 fusion protein which was experimentally shown to be important in its binding to its TFGBR1 receptor and its functional activity.
    Type: Grant
    Filed: January 19, 2021
    Date of Patent: February 27, 2024
    Assignee: Globetek Science Foundation
    Inventor: Samuel Dequina Bernal
  • Patent number: 11903999
    Abstract: A method of inducing cell death in a glioblastoma multiforme cancer cell is provided, the method comprising administering to the cell a combination of therapeutic agents comprising: saposin C and dioleoylphosphatidylserine (SapC-DOPS), and nucleolin aptamer AS1411, wherein cell death of the cancer cell is induced. Also provided are methods of treating glioblastoma multiforme, methods of inhibiting growth of a glioblastoma multiforme tumor, kits, and pharmaceutical compositions comprising SapC-DOPS and AS1411.
    Type: Grant
    Filed: October 15, 2018
    Date of Patent: February 20, 2024
    Assignee: University of Cincinnati
    Inventors: Xiaoyang Qi, Nikhil Shukla
  • Patent number: 11879158
    Abstract: The present disclosure provides a system and method for the detection of rare mutations and copy number variations in cell free polynucleotides. Generally, the systems and methods comprise sample preparation, or the extraction and isolation of cell free polynucleotide sequences from a bodily fluid; subsequent sequencing of cell free polynucleotides by techniques known in the art; and application of bioinformatics tools to detect rare mutations and copy number variations as compared to a reference. The systems and methods also may contain a database or collection of different rare mutations or copy number variation profiles of different diseases, to be used as additional references in aiding detection of rare mutations, copy number variation profiling or general genetic profiling of a disease.
    Type: Grant
    Filed: March 16, 2022
    Date of Patent: January 23, 2024
    Assignee: Guardant Health, Inc.
    Inventor: AmirAli Talasaz
  • Patent number: 11846622
    Abstract: Provided are aptamer-functionalized graphene sensors, capable of detecting various analytes, including toxins, at comparatively low concentrations. Also provided are methods of fabricating and using such aptamer-functionalized graphene sensors.
    Type: Grant
    Filed: March 12, 2019
    Date of Patent: December 19, 2023
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Alan T. Johnson, Jr., Jinglei Ping, Steven Vitale, Chengyu Wen
  • Patent number: 11834498
    Abstract: The present disclosure provides biparatopic antibodies comprising polypeptides that bind to folate receptor alpha (FR?) compositions comprising such biparatopic antibodies. In a specific aspect, the biparatopic antibodies bind to FR? and modulate FR? activity. The present disclosure also provides methods for treating disorders, such as cancer, by administering a biparatopic antibody that specifically binds to FR? and modulates FR? activity.
    Type: Grant
    Filed: June 10, 2022
    Date of Patent: December 5, 2023
    Assignee: ImmunoGen, Inc.
    Inventors: Olga Ab, Neeraj Kohli, Thomas Chittenden, Julianto Setiady
  • Patent number: 11827703
    Abstract: The present disclosure relates to antibody-drug conjugates (ADCs) wherein one or more active agents are conjugated to an anti-CD19 antibody through a linker. The linker may comprise a unit that covalently links active agents to the antibody. The disclosure further relates to monoclonal antibodies and antigen binding fragments, variants, multimeric versions, or bispecifics thereof that specifically bind CD19, as well as methods of making and using these anti-CD19 antibodies and antigen-binding fragments thereof in a variety of therapeutic, diagnostic and prophylactic indications.
    Type: Grant
    Filed: May 9, 2019
    Date of Patent: November 28, 2023
    Assignees: LegoChem Biosciences, Inc., NovImmune, SA
    Inventors: Ho Young Song, Yun Hee Park, Sung Min Kim, Hyoung Rae Kim, Ji Hye Oh, Hyun Min Ryu, Jeiwook Chae, Yeong Soo Oh, Yong Zu Kim, Maureen Deehan, Nicolas Fischer
  • Patent number: 11827691
    Abstract: This invention relates to molecules, particularly polypeptides, more particularly fusion proteins that include a serpin polypeptide or an amino acid sequence that is derived from a serpin and second polypeptide comprising of at least one the following: an Fc polypeptide or an amino acid sequence that is derived from an Fc polypeptide; a cytokine targeting polypeptide or a sequence derived from a cytokine targeting polypeptide; a (whey acidic protein) WAP domain containing polypeptide or a sequence derived from a WAP containing polypeptide; and an albumin polypeptide or an amino acid sequence that is derived from a serum albumin polypeptide. This invention also relates to methods of using such molecules in a variety of therapeutic and diagnostic indications, as well as methods of producing such molecules.
    Type: Grant
    Filed: June 22, 2020
    Date of Patent: November 28, 2023
    Assignee: InhibRx, Inc.
    Inventors: Brendan P. Eckelman, John C. Timmer, Peter L. Nguy, Grant B. Guenther, Quinn Deveraux
  • Patent number: 11808722
    Abstract: Sensors having an advantageous design and methods for fabricating such sensors are generally provided. Some sensors described herein comprise pairs of electrodes having radial symmetry, pairs of nested electrodes, and/or nanowires. Some embodiments relate to fabricating electrodes by methods in which nanowires are deposited from a fluid contacted with a substrate in a manner such that it evaporates and is replenished.
    Type: Grant
    Filed: August 29, 2022
    Date of Patent: November 7, 2023
    Assignee: NanoDX, Inc.
    Inventors: Farhad Khosravi, David Bastable, Sergey A. Dryga
  • Patent number: 11795203
    Abstract: Disclosed are a protein heterodimer and the use thereof. The protein heterodimer comprises a first polypeptide chain and a second polypeptide chain different from the first polypeptide chain, wherein the first polypeptide chain comprises IL(interleukin)12a and a first factor fused to IL12a, the second polypeptide chain comprises IL12b and a second factor fused to IL12b, and the first factor and the second factor are each independently selected from a group consisting of: IL2, GMCSF(granulocyte-macrophage colony-stimulating factor), IL7, IL15, IL21 and FLT3L(FMS-like tyrosine kinase 3 ligand). The protein heterodimer can be used for treating tumors.
    Type: Grant
    Filed: July 30, 2019
    Date of Patent: October 24, 2023
    Inventor: Jinyu Zhang
  • Patent number: 11795456
    Abstract: Compositions and methods for treating or inactivating viruses in a subject in need thereof are provided herein. Exemplary compositions include nucleic acids encoding an RNA-guided endonuclease and a guide RNA that is complementary to a target sequence in a virus. The RNA-guided endonuclease specifically targets viral nucleic acid sequences for destruction and suppression of that virus in a host cell in vitro or in vivo.
    Type: Grant
    Filed: April 15, 2019
    Date of Patent: October 24, 2023
    Assignee: Georgia Tech Research Corporation
    Inventors: Swapnil Bawage, Pooja M. Tiwari, Philip J. Santangelo
  • Patent number: 11786603
    Abstract: Provided herein are methods and compositions for site-specific conjugation of antibodies in the presence of a transglutaminase.
    Type: Grant
    Filed: February 24, 2017
    Date of Patent: October 17, 2023
    Assignee: REGENERON PHARMACEUTICALS, INC.
    Inventors: Amy Han, William Olson, Christopher D'Souza
  • Patent number: 11732038
    Abstract: The invention relates to novel cell-binding agent-cytotoxic agent conjugates, wherein the cell-binding agent (CBA) is covalently linked to the cytotoxic agent through an aldehyde group obtained from oxidation of a 2-hydroxyethylamine moiety on the CBA. The invention also provides methods of preparing the conjugates of the present invention. The invention further provides composition and methods useful for inhibiting abnormal cell growth or treating a proliferative disorder in a mammal using the conjugates of the invention.
    Type: Grant
    Filed: February 12, 2021
    Date of Patent: August 22, 2023
    Assignee: IMMUNOGEN, INC.
    Inventors: Nathan Elliott Fishkin, Daniel J. Tavares, Lingyun Rui, Luke B. Harris, Manami Shizuka, Michael Louis Miller, Ravi V. J. Chari
  • Patent number: 11733246
    Abstract: The present application provides stable heterobiligands made up of peptide-based FOLR1 ligands and folate (the ligand of FOLR1) and methods of use of the heterobiligands as detection, imaging, diagnostic, and therapeutic agents. The application further provides methods of manufacturing FOLR1 heterobiligands, capture agents, and imaging agents.
    Type: Grant
    Filed: January 12, 2022
    Date of Patent: August 22, 2023
    Assignee: INDI MOLECULAR, INC.
    Inventors: Heather Dawn Agnew, Anders Eliasen, Bert Tsunyin Lai
  • Patent number: 11674883
    Abstract: The present invention is related to correct the errors in instruments, operation, and others using intelligent monitoring structures and machine learning, and others.
    Type: Grant
    Filed: December 29, 2021
    Date of Patent: June 13, 2023
    Assignee: Essenlix Corporation
    Inventors: Stephen Y. Chou, Wei Ding, Wu Chou, Jun Tian, Yuecheng Zhang, Mingquan Wu, Xing Li
  • Patent number: 11661631
    Abstract: Disclosed herein include systems, methods, compositions, and kits for determining protein expression and gene expression simultaneously and for sample indexing. In some embodiments, an oligonucleotide associated with a cellular component-binding reagent (e.g., an antibody) comprises one or more of a unique molecular label sequence, a primer adapter, antibody-specific barcode sequence, an alignment sequence, and/or a poly(A) sequence. In some embodiments, the oligonucleotide is associated with the cellular component-binding reagent via a linker (e.g., 5AmMC12).
    Type: Grant
    Filed: January 21, 2020
    Date of Patent: May 30, 2023
    Assignee: Becton, Dickinson and Company
    Inventors: Eleen Shum, Katherine Lazaruk, Dennis E. Prosen, Devon Jensen, David Rosenfeld, Janice H. Lai, James Ghadiali, Christina Chang
  • Patent number: 11662349
    Abstract: The present invention relates to sensors and methods for detecting carbohydrates, such as lactose, in a sample. The sensors and methods may also be used to determine the amount of carbohydrate in the sample.
    Type: Grant
    Filed: August 7, 2018
    Date of Patent: May 30, 2023
    Assignee: Commonwealth Scientific and Industrial Research Organisation
    Inventors: Karine Caron, Stephen Charles Trowell
  • Patent number: 11560423
    Abstract: The present invention relates to isolated monoclonal antibodies (mAbs) and/or antigen-binding fragments thereof that specifically recognize indoxyl sulfate, a protein-bound uremic toxin, and uses of such isolated anti-IS mAbs and/or antigen-binding fragments thereof to create immunoassay methods applied in theragnosis of IS-related diseases.
    Type: Grant
    Filed: June 15, 2020
    Date of Patent: January 24, 2023
    Assignee: LEADGENE BIOMEDICAL, INC.
    Inventors: Yung-Chun Chuang, Yu-Wei Cheng, Chih-Hui Kao
  • Patent number: 11542339
    Abstract: Provided is an antibody for treating a cancer, more specifically, an anti-CD43 antibody binding to an extracellular domain of CD43, compositions for treating a cancer or inhibiting a cancer stem cell comprising the antibody as an active ingredient, and methods for screening an agent of inhibiting a cancer stem cell.
    Type: Grant
    Filed: May 11, 2020
    Date of Patent: January 3, 2023
    Assignee: APROGEN INC.
    Inventors: Kwon Pyo Hong, Sangsoon Yoon, Irene Koukoulas, Vincent Batori, Briony Cristiano, David S Wilson, Jr., George Kopsidas
  • Patent number: 11542301
    Abstract: The present application addresses the problem of providing an Fc-binding protein having an improved antibody separation ability. The present application also addresses the problem of providing a high-accuracy antibody separation method using an insoluble carrier having the protein immobilized thereon. The problems can be solved by: an Fc-binding protein in which at least an amino acid substitution at a specific position therein occurs and which has reduced affinity for an antibody; and an antibody separation method including allowing an equilibration buffer solution to pass through a column in which an insoluble carrier having the protein immobilized thereon is filled to equilibrate the column, adding a solution containing an antibody to cause the adsorption of the antibody onto the carrier, and eluting the antibody adsorbed on the carrier using an elution solution.
    Type: Grant
    Filed: February 7, 2018
    Date of Patent: January 3, 2023
    Assignee: TOSOH CORPORATION
    Inventors: Yosuke Terao, Yoshiharu Asaoka, Ryoko Otake, Satoshi Endo, Naoki Yamanaka, Yukie Yamamoto, Seigo Oe
  • Patent number: 11434295
    Abstract: The present invention relates to immunoglobulins that bind Fc?RIIb+ cells and coengage the antigen on the cell's surface and an Fc?RIIb on the cell's surface, methods for their generation, and methods for using the immunoglobulins.
    Type: Grant
    Filed: November 10, 2011
    Date of Patent: September 6, 2022
    Assignee: XENCOR, INC.
    Inventors: Seung Yup Chu, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar, Gregory L. Moore, Igor Vostiar
  • Patent number: 11406719
    Abstract: The present invention provides dichromic fluorescent compounds, as well as processes for making and methods for using the dichromic fluorescent compounds.
    Type: Grant
    Filed: April 4, 2016
    Date of Patent: August 9, 2022
    Assignee: Washington University
    Inventors: Samuel Achilefu, Zongren Zhang, Mikhail Berezin
  • Patent number: 11353450
    Abstract: Methods and Raman detection agents for detecting an analyte in a sample are provided. Methods described herein may comprise steps of providing a 3D diagnostic substrate presenting a capture agent for the analyte or an analyte complex; exposing the sample to the substrate and to a Raman detection agent, allowing analyte in the sample to bind to the capture agent of the diagnostic substrate and an affinity component of the Raman detection agent; and detecting the Raman detection agent bound to the 3D diagnostic substrate by Raman spectroscopy, thereby detecting the presence of the analyte in the sample. Raman detection agents described herein may comprise a Raman signal-enhancing metal nanoparticle carrying both a Raman reporter and an affinity component for binding to the analyte or the complex formed between the analyte and the capture agent on the 3D diagnostic substrate.
    Type: Grant
    Filed: November 25, 2017
    Date of Patent: June 7, 2022
    Assignee: MedMira Inc.
    Inventors: Neeraj Vats, Hok Ping Hui
  • Patent number: 11279771
    Abstract: The application discloses bispecific TFPI antibodies that are capable of specifically and simultaneously binding two epitopes within TFPI (1-161). Such bispecific antibodies strongly enhance thrombin generation by neutralising TFPI, even where the concentration of TFPI is elevated. Bispecific antibodies of the invention or compositions comprising them may be used for the treatment of subjects with a coagulopathy.
    Type: Grant
    Filed: September 17, 2015
    Date of Patent: March 22, 2022
    Assignee: NOVO NORDISK A/S
    Inventors: Helle Heibroch Petersen, Berit Olsen Krogh, Jens Breinholt, Mikael Kofod-Hansen, Ida Hilden
  • Patent number: 11220556
    Abstract: The present invention provides compounds producing compounds having the structure (I). Wherein A is a first polypeptide component of the compound; wherein C is a second polypeptide component of the compound, which polypeptide component comprises consecutive amino acids which (i) are identical to a stretch of consecutive amino acids present in a chain of an Fc domain of an antibody; (ii) bind to an Fc receptor; and (iii) have at their N-terminus a sequence selected from the group consisting of a cysteine, selenocysteine, CP, CPXCP (where X=P, R, or S) (SEQ ID NOs: 128-130), CDKTHTCPPCP (SEQ ID NO: 131), CVECPPCP (SEQ ID NO 132), CCVECPPCP (SEQ ID NO 133) and CDTPPPCPRCP (SEQ ID NO 134), wherein B is a chemical structure linking A and C; wherein the dashed line between B and C represents a peptidyl linkage; wherein the solid line between A and B represents a nonpeptidyl linkage comprising the structure (II).
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: January 11, 2022
    Assignee: BIOMOLECULAR HOLDINGS LLC
    Inventor: Daniel Capon
  • Patent number: 11098120
    Abstract: Methods of modulating the immune systems of patients suffering from cancers that do not bear, or do not uniformly bear, surface CD3 are provided. The methods involve administering an anti-CD3 immunotoxin (e.g. A-dmDT390-bisFv(UCHT1)), to the patient so as to cause the patient's immune system to recognize and destroy non-CD3 cancer cells.
    Type: Grant
    Filed: October 5, 2018
    Date of Patent: August 24, 2021
    Assignee: ANGIMMUNE, LLC
    Inventor: David M. Neville
  • Patent number: 11066459
    Abstract: The present invention provides a compound having the structure: A-B - - - Z wherein A is a biologically active structure of the compound; wherein Z is a protein component of the compound, which protein component comprises one or more polypeptides, wherein at least one of the one or more polypeptides comprises consecutive amino acids which (i) are identical to a stretch of consecutive amino acids present in a chain of an Fc domain of an antibody; (ii) bind to an Fc receptor; and (iii) have at their N-terminus a sequence selected from the group consisting of a cysteine or selenocysteine; wherein the dashed line between B and Z represents a peptidyl linkage; and wherein the solid line between A and B represents a nonpeptidyl linkage, as well as intermediates dimers thereof, and processes of producing the compounds of the invention.
    Type: Grant
    Filed: March 13, 2015
    Date of Patent: July 20, 2021
    Assignee: BIOMOLECULAR HOLDINGS LLC
    Inventor: Daniel J. Capon
  • Patent number: 10660966
    Abstract: A method for removing or controlling or quantifying the presence of aldehydes, in particular acetaldehyde, is described. Such a method is useful in prolonging the shelf life of a pharmaceutical product.
    Type: Grant
    Filed: December 4, 2015
    Date of Patent: May 26, 2020
    Assignee: GE HEALTHCARE LIMITED
    Inventors: Torgrim Engell, Julian Grigg, Dimitrios Mantzilas, Dag M. Evje
  • Patent number: 10655168
    Abstract: Compositions comprising covalently modified and mutated biotin-binding proteins, particularly biotin-binding proteins having a negative charge at physiological pH, are provided. Methods of producing such proteins are also provided, as are methods of immobilizing, sequencing, and making nucleic acids employing such proteins.
    Type: Grant
    Filed: December 21, 2018
    Date of Patent: May 19, 2020
    Assignee: Pacific Biosciences of California, Inc.
    Inventors: Satwik Kamtekar, Lubomir Sebo, Leewin Chern, Thomas Linsky, Jeremiah Hanes, Erik Miller, Ying Yang, Stephen Yue
  • Patent number: 10370399
    Abstract: The invention relates generally to a calicheamicin molecule activated with a leaving group. The invention further relates generally to an antibody-drug conjugate comprising an antibody directly conjugated by a disulfide to one or more calicheamicin molecules.
    Type: Grant
    Filed: October 19, 2016
    Date of Patent: August 6, 2019
    Assignee: Genentech, Inc.
    Inventor: Thomas Pillow
  • Patent number: 10314922
    Abstract: A type of trimaleimide linkers and uses thereof are disclosed. The trimaleimide linkers can be applied for preparation of antibody-drug conjugate as shown by formula I: L-(T-A-D)n I wherein, L is an antibody, antibody fragment or protein; T is a trimaleimide linker; A is a cleavable linker group or a noncleavable linker; D is a drug; n is an integer ranging from 1 to 8.
    Type: Grant
    Filed: May 17, 2016
    Date of Patent: June 11, 2019
    Assignee: NewBio Therapeutics, Inc.
    Inventors: Nianhe Han, Deqiang An, Di Zeng, Baoxiang Wang, Hang Yang, Li Jian, Chun Yang
  • Patent number: 10280214
    Abstract: Herein are reported glycosylated repeat-motif-molecule conjugate of the following formula: (repeat-motif-molecule?linkern)m?conjugation partner?(linkero?repeat-motif-molecule)p, wherein n and o are independently of each other and independently for each value of m and p integer values of 0 or 1, and m and p are independently of each other integer values of 0 or 1 or 2 or 3 or 4 or 5 or 6 or 7, and wherein the repeat-motif-molecule conjugate comprises at least one oligosaccharide attached to a glycosylation site. Also reported are encoding nucleic acids and method for producing these repeat-motif-conjugates in mammalian cells.
    Type: Grant
    Filed: May 4, 2012
    Date of Patent: May 7, 2019
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Stephan Fischer, Sabine Imhof-Jung, Erhard Kopetzki
  • Patent number: 9522958
    Abstract: Provided is a cancer therapeutic agent comprising a cancer targeting molecule linked to a CpG oligodeoxynucleotide. Also provided are methods of reducing the size of a tumor or inhibiting the growth of cancer cells in an individual or inhibiting the development of metastatic cancer, comprising administering an effective amount of the cancer therapeutic agent. The methods may also include reducing immunoregulatory T cell activity in the individual.
    Type: Grant
    Filed: September 8, 2011
    Date of Patent: December 20, 2016
    Assignee: University of Southern California
    Inventors: Alan L. Epstein, Leslie A. Khawli
  • Patent number: 9410044
    Abstract: Embodiments of the invention include linking agents including borate, borazine, or boronate groups and coatings and devices that incorporate such linking agents, along with related methods. Other embodiments are also included herein.
    Type: Grant
    Filed: May 2, 2013
    Date of Patent: August 9, 2016
    Assignee: SurModics, Inc.
    Inventor: Aleksey V. Kurdyumov
  • Patent number: 9155800
    Abstract: A fusion protein comprising at least one Type 1 Ribosome Inactivating Protein, polypeptide B; and at least one polypeptide A capable of viral entry inhibition; and/or at least one Cationic AntiMicrobial Peptide, polypeptide C.
    Type: Grant
    Filed: January 9, 2012
    Date of Patent: October 13, 2015
    Assignee: VALIANT BIOPHARMA SDN BHD
    Inventors: Muhammad Sagaf Abu Bakar, Ag., Eng Huan Ung
  • Publication number: 20150147332
    Abstract: An isolated protein or peptide selected from the group consisting of Bordetella colonization factor A (BcfA) protein and antigenic fragments thereof is described, along with an isolated nucleic acid encoding the same, antibodies that bind to the same, methods of producing an immune response in a mammalian subject in need thereof by administering the proteins, peptides or antibodies, and pharmaceutical compositions comprising the same.
    Type: Application
    Filed: September 26, 2014
    Publication date: May 28, 2015
    Inventors: Rajendar K. Deora, Meenu Mishra, Neelima Sukumar
  • Publication number: 20150147345
    Abstract: This document relates to conjugates of a biologically active molecule or a derivative thereof and functionalized (e.g., mono- or bi-functional) polymers (e.g., polyethylene glycol and related polymers) as well as methods and materials for making and using such conjugates.
    Type: Application
    Filed: June 12, 2013
    Publication date: May 28, 2015
    Inventor: Marek Kwiatkowski
  • Publication number: 20150147752
    Abstract: The present invention relates to novel iridium-based Ir(III) luminescent complexes, conjugates comprising these complexes as a label and their application, e.g. in the electrochemiluminescence based detection of an analyte.
    Type: Application
    Filed: January 30, 2015
    Publication date: May 28, 2015
    Inventors: Frank Bergmann, Robert Cysewski, Luisa de Cola, Sebastian Dziadek, Jesus Miguel Fernandez Hernandez, Hans-Peter Josel, Elena Longhi, Christoph Seidel
  • Publication number: 20150147274
    Abstract: Antibodies which are antagonists of the human HGF receptor (MET), wherein the antibodies specifically bind to amino acid residues 568-741 of human MET (SEQ ID No: 1) with high affinity.
    Type: Application
    Filed: November 30, 2012
    Publication date: May 28, 2015
    Inventors: Danielle Marie Di Cara, John McCafferty, Ermanno Gherardi, Anthony Richard Pope
  • Patent number: 9040310
    Abstract: Disclosed herein are antibody-nanoparticle conjugates that include two or more nanoparticles (such as gold, palladium, platinum, silver, copper, nickel, cobalt, iridium, or an alloy of two or more thereof) directly linked to an antibody or fragment thereof through a metal-thiol bond. Methods of making the antibody-nanoparticle conjugates disclosed herein include reacting an arylphosphine-nanoparticle composite with a reduced antibody to produce an antibody-nanoparticle conjugate. Also disclosed herein are methods for detecting a target molecule in a sample that include using an antibody-nanoparticle conjugate (such as the antibody-nanoparticle conjugates described herein) and kits for detecting target molecules utilizing the methods disclosed herein.
    Type: Grant
    Filed: April 27, 2011
    Date of Patent: May 26, 2015
    Assignee: Ventana Medical Systems, Inc.
    Inventors: Julia Ashworth-Sharpe, Chol Steven Yun, Zhanna Zhilina, Adrian E. Murillo, Donald D. Johnson, Michael Farrell, Jerome W. Kosmeder, Christopher Bieniarz
  • Publication number: 20150140684
    Abstract: A target affinity material comprising a biodegradable polymer, wherein the biodegradable polymer comprises one or more solid particles and one or more materials that specifically binds to a target, as well as related methods and kits.
    Type: Application
    Filed: July 17, 2014
    Publication date: May 21, 2015
    Inventors: Ga-hee KIM, Hyun-ju Kang, Ye-ryoung Yong, Jong-myeon Park
  • Publication number: 20150133618
    Abstract: The invention discloses a method of separating a biomolecule from at least one other component in a liquid, comprising a step of contacting said liquid with a separation matrix comprising a solid support and polymer chains bound to said solid support. The polymer chains comprise units derived from a first monomer of structure CH2?CH-L-X, where L is a covalent bond or an alkyl ether or hydroxysubstituted alkyl ether chain comprising 2-6 carbon atoms, and X is a sulfonate or phosphonate group.
    Type: Application
    Filed: April 22, 2013
    Publication date: May 14, 2015
    Inventors: Jesper Hanssen, Gustav Rodrigo, Tobias E Soderman
  • Patent number: 9029508
    Abstract: The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.
    Type: Grant
    Filed: April 28, 2009
    Date of Patent: May 12, 2015
    Assignee: AbbVie Inc.
    Inventors: Tariq Ghayur, Susan E. Morgan-Lappe, Edward B. Reilly, Gillian A. Kingsbury, Andrew Phillips, Jieyi Wang, Randy L. Bell, Suzanne M. Norvell, Yingchun Li, Junjian Liu, Hua Ying
  • Patent number: 9029509
    Abstract: The present disclosure relates to binding agents (e.g. antibodies) that bind to and/or modulate the activity of a urokinase plasminogen activator receptor (uPAR/CD87), compositions comprising the antibodies, and methods involving use of the antibodies or compositions.
    Type: Grant
    Filed: February 11, 2011
    Date of Patent: May 12, 2015
    Assignee: The Regents of the University of California
    Inventors: Charles S. Craik, Krishna Sai Duriseti, David H. Goetz
  • Publication number: 20150125397
    Abstract: Engineered multivalent and multispecific binding proteins that bind immune cell receptors and/or autoantigens are provided, along with methods of making and uses in the prevention, diagnosis, prognosis and/or treatment of disease.
    Type: Application
    Filed: October 6, 2014
    Publication date: May 7, 2015
    Inventors: Chee-Ho Choi, Tariq Ghayur, Ann Marshak-Rothstein, Krishna Moody
  • Publication number: 20150125473
    Abstract: The present invention concerns a process for the preparation of an antibody conjugate comprising the step of reacting an engineered antibody having a single inter-heavy chain disulfide bond with a conjugating reagent that forms a bridge between the two cysteine residues derived from the disulfide bond.
    Type: Application
    Filed: June 19, 2013
    Publication date: May 7, 2015
    Inventors: John Burt, Antony Godwin, George Badescu
  • Publication number: 20150125454
    Abstract: The present invention provides an antibody which binds to a fibroblast growth factor receptor.
    Type: Application
    Filed: April 9, 2013
    Publication date: May 7, 2015
    Applicant: Daiichi Sankyo Company, Limited
    Inventors: Toshiaki Ohtsuka, Chigusa Yoshimura, Toshinori Agatsuma, Atsushi Urano, Takako Kimura, Yumi Matsui, Tatsuji Matsuoka, Jun Hasegawa, Yasuki Kamai, Reimi Kawaida